

Machine learning approaches for prediction of major bleeding events in anticoagulated atrial fibrillation patients

Fatemeh Torabi, Arron Lacey, Ashley Akbari, Daniel Harris, Ronan A Lyons, Julian Halcox, Mike Gravenor

Direction of interest

I am research officer and data scientist at HDR UK

My background is in mathematical statistics and health data science

This work:

Ethical approval from Swansea University Research Committee: 2018-0056

Information Governance Review Panel (IGRP): SAIL0866

**Background
and
Introduction**

Methodology

Results

**Conclusion
and
Discussion**

HAS-BLED

(Pisters et al., 2010)

Background

- Atrial fibrillation (AF) increases risk of stroke by 5 to 7 folds.
- Anticoagulant (AC) drugs can prevent blood clots formation.
- Appropriate use of AC drugs can reduce stroke risk by two-thirds in AF patients.
- Bleeding is the main side effect of AC drugs that influences clinical decision of anticoagulation to some extent.
- Various bleeding risk schemes were introduced and used to evaluate risk of bleeding in AF patients.
- None of these schemes to date have been validated using machine learning classification approaches.

ATRIA

(Fang et al., 2011)


ORBIT

(O' Brien et al., 2015)

ABC

(Hijazi et al., 2016)

HAS-BLED (Pisters et al., 2010)

The diagram illustrates the HAS-BLED scale, a tool for assessing bleeding risk in patients on anticoagulants. It consists of seven horizontal red bars of varying lengths, each representing a clinical factor. To the right of each bar is a blue oval containing a weight (1 or 2). The bars are arranged in a descending staircase pattern from top-left to bottom-right. The factors and their weights are: Hypertension (1), Abnormal renal/liver function (1 or 2), Stroke (1), Bleeding history or predisposition (1), Labile INR (1), Elderly (age over 65) (1), and Drug usage / alcohol concomitantly (1 or 2).

Hypertension	1
Abnormal renal/liver function	1or2
Stroke	1
Bleeding history or predisposition	1
Labile INR	1
Elderly (age over 65)	1
Drug usage / alcohol concomitantly	1or2

Different approaches to risk prediction

All four studies identified a set of contributing factors and used a method to develop the prediction models

Study	Method	Data	Subject counts	Reported AUC
HAS-BLED (Pisters et al., 2010)	Multivariate logistic regression	Large population database: Euro Heart Survey	5,333	0.72
ATRIA (Fang et al., 2011)	Time-varying cox proportional hazard ratio with split-sample	Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA)	13,559	0.69
ORBIT (O'Brien et al., 2015)	Cox proportional hazard ratio	Outcome Registry for Better Informed Treatment of AF (ORBIT-AF)	7,411	0.69-0.67
ABC (Hijazi et al., 2016)	Cox proportional hazard ratio	ATIRSTOTLE and RE_LY trials	14,537 (ARISTOTLE trial) 8,468 (RE-LY trial)	0.68




Objectives

- Validate HAS-BLED in Welsh AF population


- Comparing performance of various models in predicting bleeding events


[illegible]

Data was accessed 2000-01-01 to 2018-01-01
Study period: 2017-01-01 to 2018-01-01



Metadata of all created fields

[illegible]



WLGP: Welsh Longitudinal General Practice | PEDW: Patient Episode Dataset for Wales
AC: AntiCoagulant drugs
All counts in the above figure are distinct patient counts

Comorbidities

Hypertension

Abnormal Renal Function

Abnormal Liver Function

Stroke

Prior bleeding

Labile International Normalized Ratio

Elderly

Drugs or Medications

Alcohol use

BMI

Smoking

Congestive Heart Failure

Diabetes

Vascular disease

Gender

Modelling

STEP 1

Validated HAS-BLED by using same set of variables as (Pisters et al. 2010) in a logistic regression model on SAIL AF cohort.

The delta features were also added to this model. (Chao et al., 2018).

STEP 2


Variables from HAS-BLED score were evaluated in: Cox proportional hazard ratio

In addition we evaluated all clinically relevant variables.

STEP 3

The logistic modelling approach was compared to two different machine learning approaches for prediction:
Random Forest
Naïve Bayes

Delta feature (Chao et al.,2018): absolute changes in baseline comorbidities within study period



Delta features= |comorbidities – Baseline comorbidities|

Follow-up of 2018-01-01

Baseline of 2017-01-01

HAS-BLED
CHA₂DS₂VASc

Delta features HAS-BLED



38,784

(Mean age of 76 and 43.5% female)

Average follow-up 96% of study window: total of 37,133 person years in study

Random Forest

- Each tree is identically distributed as each one is grown using a randomization strategy: using bootstrapping and have a finite outcome => for a given set of samples, a statistic of interest will converge to a mean (WLLN).
- WLLN: independence & identically distributed:
- $$P(|X - \mu| \geq k) \leq \frac{\text{var}(X)}{k^2}$$

Naïve Bayes


- Probabilistic classifier based on conditional probability of event of interest and Bayes theorem:
- $$p(C_k|x) = \frac{p(C_k)p(x|C_k)}{p(x)}$$
- $$\text{posterior} = \frac{\text{prior} \cdot \text{likelihood}}{\text{evidence}}$$




Results

Baseline Characteristics				No bleed	Bleed	P-value
n				36368	2416	
Age mean(sd)				75.93 (9.85)	77.43 (9.51)	<0.001
18-65				4268 (11.7)	217 (9.0)	
65-74				11880 (32.7)	699 (28.9)	
75+				20220 (55.6)	1500 (62.1)	
Female				15875 (43.7)	981 (40.6)	0.147
CHA2DS2Vasc	score			3.43 (1.46)	3.76 (1.52)	<0.001
0				738 (2.0)	26 (1.1)	
1				2595 (7.1)	117 (4.8)	
2				6187 (17.0)	345 (14.3)	
3				9343 (25.7)	590 (24.4)	
4				9156 (25.2)	609 (25.2)	
5				5537 (15.2)	417 (17.3)	
6				2217 (6.1)	231 (9.6)	
7				521 (1.4)	60 (2.5)	
8				68 (0.2)	15 (0.6)	
9				6 (0.0)	6 (0.2)	
HAS-BLED	score	INR5		2.17 (1.03)	2.39 (1.09)	<0.001
0				1221 (3.4)	52 (2.2)	
1				8260 (22.7)	442 (18.3)	
2				14362 (39.5)	893 (37.0)	
3				8968 (24.7)	665 (27.5)	
4				2953 (8.1)	282 (11.7)	
5+				604 (1.6)	82 (3.4)	
HAS-BLED	score	INR8		2.01 (0.97)	2.21 (1.02)	<0.001
0				1401 (3.9)	58 (2.4)	
1				9554 (26.3)	538 (22.3)	
2				15315 (42.1)	960 (39.7)	
3				7746 (21.3)	612 (25.3)	
4				2021 (5.6)	206 (8.5)	
5+				333 (0.9)	44 (1.8)	
History of bleed (hospital)				8160 (22.4)	842 (34.9)	0.226
History of bleed (GP)				2672 (7.3)	344 (14.2)	0.313
Stroke				5558 (15.3)	369 (15.3)	0.267
Congestive Heart failure				10871 (29.9)	827 (34.2)	0.19
Hypertension				20490 (56.3)	1395 (57.7)	0.147
Liver disease				1085 (3.0)	80 (3.3)	0.339
Renal disease				650 (1.8)	99 (4.1)	0.346
Labile INR (over5)				9837 (27.0)	736 (30.5)	0.203
Labile INR (over8)				4248 (11.7)	301 (12.5)	0.288
Alcohol consumption				893 (2.5)	45 (1.9)	0.342
Vascular disease				12646 (34.8)	960 (39.7)	0.17
Diabetes				9837 (27.0)	716 (29.6)	0.203
Antiplatelet drugs				23315 (64.1)	1586 (65.6)	0.167

BLEED




NO-BLEED



Validation of HAS-BLED

	Estimate	Std. Error	z value	Pr(> z)
(Intercept)	-3.19231	0.08112	-39.354	< 2e-16
Hypertension-BL	0.01861	0.04288	0.434	0.6643
Abnormal Liver function-BL	0.09775	0.11961	0.817	0.4138
Abnormal renal function-BL	0.75325	0.11117	6.776	1.24E-11
Stroke-BL	-0.07819	0.05896	-1.326	0.1848
Any major bleeding-BL	0.58798	0.04488	13.101	< 2e-16
INR 5 or above-BL	0.10162	0.04631	2.195	0.0282
Age 65-74	0.10803	0.08017	1.348	0.1778
Age 75+	0.30986	0.07567	4.095	4.22E-05
Drug and medication use	0.07873	0.04454	1.768	0.0771
Alcohol-BL	-0.21876	0.15719	-1.392	0.164




Hazard ratio of HAS-BLED variables

Covariates Entire sample(n=35,784) Number of events (n=2,416)					
	Coefficient	HR	Lower 95% CI	Upper 95% CI	Pr(> z)
Hypertension-BL	0.01721	1.01736	0.9381	1.103	0.6776
Abnormal Liver function-BL	0.09907	1.10414	0.8815	1.383	0.3887
Abnormal renal function-BL	0.71825	2.05084	1.6751	2.511	3.52E-12
Stroke-BL	-0.07029	0.93213	0.8338	1.042	0.2163
Any major bleeding-BL	0.56805	1.76482	1.6222	1.92	< 2e-16
INR 5 or above-BL	0.10004	1.10521	1.0128	1.206	0.0247
Age 65-74	0.10625	1.11209	0.9545	1.296	0.173
Age 75+	0.30842	1.36128	1.1785	1.572	2.75E-05
Drug and medication use	0.07643	1.07942	0.9922	1.174	0.0755
Alcohol-BL	-0.20786	0.81232	0.602	1.096	0.1738
Concordance= 0.592 (se = 0.006)					
Likelihood ratio test= 270.9 on 10 df, p=<2e-16					
Wald test= 295.9 on 10 df, p=<2e-16					
Score (logrank) test = 305.9 on 10 df, p=<2e-16					

Hazard ratio of Bleeds stratified by Gender

Figure 3: survival Time to major bleeding events for male and females



Covariates

Entire sample(n=35,784)

Number of events (n=2,416)

	Coefficient	HR	Lower 95% CI	Upper 95% CI	Pr(> z)
Gender	-0.12175	0.88537	0.8163	0.9603	0.00329


Concordance= 0.515 (se = 0.005)

Likelihood ratio test= 8.7 on 1 df, p=<0.003

Wald test= 8.64 on 1 df, p=<0.003

Score (logrank) test = 8.65 on 1 df, p=<0.003

Figure 4: survival Time to major bleeding events for HASBLED_INR5 levels



Hazard ratio of bleed for levels of CHA₂DS₂VASc score

Covariates Entire sample(n=35,784) Number of events (n=2,416)					
	Coefficient	HR	Lower 95% CI	Upper 95% CI	Pr(> z)
Hypertension-BL	-0.11595	0.89052	0.8125	0.976	1.32E-02
Abnormal Liver function-BL	0.05324	1.05468	0.8416	1.3217	0.64379
Abnormal renal function-BL	0.62206	1.86275	1.5182	2.285	2.49E-09
Stroke-BL	-0.11332	0.89287	0.798	0.9991	0.04812
Any major bleeding-BL	0.54696	1.72798	1.5879	1.8804	< 2e-16
INR 5 or above-BL	0.07044	1.07298	0.9828	1.1715	0.11594
Age 65-74	-0.07152	0.93098	0.7825	1.1076	0.41983
Age 75+	0.01182	1.01189	0.8421	1.2159	0.89966
Drug and medication use	0.07537	1.07828	0.9911	1.1731	0.07963
Alcohol-BL	-0.20036	0.81843	0.6066	1.1043	0.18986
CHADSVASC_BL2	0.26483	1.30321	0.8454	2.0088	0.23034
CHADSVASC_BL3	0.45974	1.58367	1.0366	2.4194	0.03348
CHADSVASC_BL4	0.56999	1.76824	1.1498	2.7193	0.00944
CHADSVASC_BL5	0.60841	1.83751	1.1857	2.8478	0.00649
CHADSVASC_BL6	0.70665	2.0272	1.2973	3.1678	0.00192
CHADSVASC_BL7	0.97367	2.64764	1.6726	4.1912	3.26E-05
CHADSVASC_BL8	1.10446	3.01759	1.8122	5.0247	2.18E-05
CHADSVASC_BL9	1.71544	5.55913	2.8332	10.9077	6.09E-07
CHADSVASC_BL10	3.08568	21.88232	8.7431	54.7673	4.33E-11

Concordance= 0.602 (se = 0.006)


Likelihood ratio test= 345.1 on 19 df, p=<2e-16

Wald test= 394.5 on 19 df, p=<2e-16


Score (logrank) test = 432.1 on 19 df, p=<2e-16


Logistic regression model with Delta features



	Estimate	Std. Error	z value	Pr(> z)
(Intercept)	-3.26863	0.083548	-39.123	< 2e-16
HYPT_GP_BL	0.006104	0.043383	0.141	0.888113
LIV_HAS_COMB_BL	-0.17641	0.127115	-1.388	0.165196
RENAL_HAS_GP_BL	0.629284	0.117768	5.343	9.12E-08
SEX_FEMALE	-0.19863	0.044009	-4.513	6.38E-06
MJ_BLEEDING_HASB_P_BL	0.484852	0.046263	10.48	< 2e-16
MJ_BLEEDING_GP_BL	0.623708	0.063883	9.763	< 2e-16
INR_5_OR_ABOVE_BL	0.06435	0.05818	1.106	0.268704
INR_8_OR_ABOVE_BL	-0.12799	0.080596	-1.588	0.112273
AGE_CAT65-74	0.108432	0.080862	1.341	0.179938
AGE_CAT75+	0.266853	0.076781	3.475	0.00051
MEDICATION_HASB_BL	0.082058	0.045055	1.821	0.068562
ALCOHOL_BL	-0.37285	0.162709	-2.292	0.021933
CHF_CHAD_COMB_BL	-0.14946	0.048965	-3.052	0.00227
CHF_CHAD_COMB	1.053622	0.055432	19.008	< 2e-16
HYPT_GP	0.04011	0.169044	0.237	0.812444
LIV_HAS_COMB	1.093149	0.144699	7.555	4.20E-14
RENAL_HAS_GP	0.25888	0.229182	1.13	0.258653
INR_5_OR_ABOVE	0.302235	0.083901	3.602	0.000315
INR_8_OR_ABOVE	-0.07188	0.103114	-0.697	0.485766
ALCOHOL	-0.06323	0.477405	-0.132	0.89464




Random Forest








Naïve Bayes classifier







Conclusion and Discussion

Model comparison

With same set of baseline and delta features, Random Forest performance is better than all other methods.



Model optimization



Strengths

- This study validated HASBLED on a very large cohort and showed there needs to be room for improvement in BLEED prediction.
- This work is transferable to other areas such as stroke prediction.

Limitations

- Use of limited number of features in models with regards to machine learning as well as only using the default parameters.

Future work

Improve machine learning methods: more models, additional features, feature selection, parameter tuning.

Extended follow-up on adverse outcomes: outcomes for those HASBLED gets wrong beyond a bleed. More deaths for those not identified? Ineffective use of resources for those falsely identified. Gaps in appropriate therapeutic options.

Applying these analysis to other areas.

Thank you!

Find the resources:

<https://github.com/FatemehTorabi>

Get in touch:

email: fatemeh.torabi@swansea.ac.uk

twitter: @Fatemetr

